Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing-Reference-Cited by-同舟云学术

Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing

Published:2022-08-31 Issue:4 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Olivença Francisco¹^ORCID,Nunes Alexandra²^ORCID,Macedo Rita³^ORCID,Pires David¹^ORCID,Silveiro Cátia¹^ORCID,Anes Elsa¹^ORCID,Miragaia Maria⁴^ORCID,Gomes João Paulo²^ORCID,Catalão Maria João¹^ORCID

Affiliation:

1. Host-Pathogen Interactions, Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal

2. Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal

3. National Reference Laboratory for Mycobacteria, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal

4. Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica António Xavier, Universidade NOVA de Lisboa, Oeiras, Portugal

Abstract

Associations between differential M. tuberculosis beta-lactam phenotypes and preexisting antimycobacterial drug resistance, strain sublineage, or specific mutational patterns were established. Importantly, we reveal that highly drug-resistant isolates of sublineage 4.3.4.2 have an increased susceptibility to beta-lactams compared with other strains.

Funder

European Society of Clinical Microbiology and Infectious Diseases

MEC | Fundação para a Ciência e a Tecnologia

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.00674-22

Reference34 articles.

1. Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis

2. Have we realized the full potential of β-lactams for treating drug-resistant TB?